What do systematic reviews say?

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

Non‐selective NSAIDs probably leads to higher withdrawals due to adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  RR 2.34 [1.33, 4.14]
  Studies not reported
  Moderate

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

Non‐selective NSAIDs probably leads to higher total adverse events compared with selective cyclo‐oxygenase‐2 inhibitors (moderate certainty).

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  RR 1.94 [1.36, 2.78]
  Studies not reported
  Moderate

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate

Non‐selective NSAIDs vs selective cyclo‐oxygenase‐2 inhibitors

• Non‐steroidal anti‐inflammatory drugs for acute gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Moderate